Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$890.80 USD

890.80
1,121,461

+6.32 (0.72%)

Updated Oct 2, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)

by Zacks Equity Research

Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

    AstraZeneca Up This Year So Far on Favorable Pipeline Updates

    by Zacks Equity Research

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

      Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe

      by Zacks Equity Research

      Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

        Glaxo's Asthma Drug Gets EU Nod for Pediatric Population

        by Zacks Equity Research

        Glaxo (GSK) gains EU approval for asthma drug Nucala as an add-on treatment for severe refractory eosinophilic asthma in children.

          AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

          by Zacks Equity Research

          AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.

            Novartis' Tafinlar/Mekinist Combo Gets EU Nod for 3rd Disease

            by Zacks Equity Research

            Novartis' (NVS) BRAF/MEK inhibitor combination, Tafinlar plus Mekinist, gets approval in the EU for adjuvant treatment of BRAF V600 mutation-positive melanoma.

              Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study

              by Zacks Equity Research

              Pfizer's (PFE) tafamidis significantly reduces rate of mortality and cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy. However, it fails to impress investors. Stock dips.

                Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events

                by Zacks Equity Research

                Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

                  Is Eli Lilly (LLY) a High-Growth Dividend Stock?

                  by Zacks Equity Research

                  Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

                    5 Reasons Why You Should Add Lilly Stock to Your Portfolio

                    by Zacks Equity Research

                    Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

                      Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

                      by Zacks Equity Research

                      Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

                        Pfizer Amends Xtandi Study Protocols to Speed Up Completion

                        by Zacks Equity Research

                        Pfizer (PFE) and Astellas Pharma announce amendment of protocols for two phase III studies evaluating Xtandi in hormone-sensitive prostate cancer, advancing anticipated completion date.

                          J&J to Appeal as Judge Confirms Jury Order in Talc Case

                          by Zacks Equity Research

                          Johnson & Johnson's (JNJ) suffers setback as Missouri judge confirms talc lawsuit jury verdict. The company intends to appeal against the decision.

                            Kinjel Shah headshot

                            Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio

                            by Kinjel Shah

                            The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.

                              Allergan Falls on FDA's Rejection of Uterine Fibroids Drug

                              by Zacks Equity Research

                              FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.

                                Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion

                                by Zacks Equity Research

                                Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.

                                  Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

                                  by Zacks Equity Research

                                  Style Box ETF report for FLQL

                                    Lilly (LLY) Hits 52-Week High, Can the Run Continue?

                                    by Zacks Equity Research

                                    Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

                                      Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

                                      by Zacks Equity Research

                                      Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

                                        Mylan (MYL) Launches Generic Version of Lilly's Adcirca

                                        by Zacks Equity Research

                                        Mylan (MYL) launches the first generic version of Lilly's Adcirca for the treatment of pulmonary arterial hypertension to improve exercise ability.

                                          Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

                                          by Zacks Equity Research

                                          Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.

                                            Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates

                                            by Zacks Equity Research

                                            Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.

                                              Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y

                                              by Zacks Equity Research

                                              Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.

                                                Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

                                                by Zacks Equity Research

                                                Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

                                                  AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

                                                  by Zacks Equity Research

                                                  AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.